Benaroya Research Institute

Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive Officer

Retrieved on: 
Thursday, March 28, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, IL-17A, Administration, Ulcerative colitis, Congress, Thymic stromal lymphopoietin, Atopic dermatitis, Alopecia areata, Inflammation, Chronic obstructive pulmonary disease, Allergy, TSLP, BCA, CMC, G&A, Interleukin 7, Benaroya Research Institute, Business analyst, Abstract, Asthma, IL-7, Research and development, Drug development, Senior management, BAFF, Eli Lilly and Company, Translational medicine, Autoimmunity, Management

Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”) a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported full year 2023 financial results and recent business highlights.

Key Points: 
  • Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”) a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported full year 2023 financial results and recent business highlights.
  • The Company has also announced the appointment of Robert Lisicki as Chief Executive Officer (CEO), effective April 8, 2024, succeeding its Founding CEO, Someit Sidhu, M.D.
  • Mr. Lisicki joined Zura Bio in January 2024 as President and Chief Operating Officer.
  • Dr. Sidhu continued, "On behalf of the Management Team and Board, I am pleased to welcome Robert as the Chief Executive Officer.

Zura Bio Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Monday, November 13, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Contract research organization, Business analyst, Scleroderma, Benaroya Research Institute, Clinical trial, Administration, Research and development, Inflammation, Strategic planning, Interleukin 7, Alopecia areata, Research fellow, G&A, Ulcerative colitis, Thymic stromal lymphopoietin, Atopic dermatitis, TSLP, R, CMC, Chronic obstructive pulmonary disease, IL-7, Hidradenitis suppurativa, Asthma, Allergy, Pharmaceutical industry, Cryptocurrency

Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”) a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced its financial results for the quarter ended September 30, 2023, and recent business highlights.

Key Points: 
  • Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”) a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced its financial results for the quarter ended September 30, 2023, and recent business highlights.
  • "In the third quarter, Zura Bio made significant progress in its strategic planning across various key areas, including Clinical, Regulatory, CMC, and Translational Science.
  • This progress positions Zura Bio for clinical trial readiness in 2024," stated Dr. Someit Sidhu, Chief Executive Officer of Zura Bio.
  • Zura Bio anticipates that its cash and cash equivalents are sufficient to fund its planned operations into 2026.

Zura Bio Enters into Sponsored Research Agreement with Benaroya Research Institute

Retrieved on: 
Tuesday, September 12, 2023
Science, Other Science, Biotechnology, Research, General Health, Health, Clinical Trials, Other Health, Maintenance, BRI, Asthma, IL-7, Research fellow, TSLP, Doctor of Philosophy, DSM-IV codes, Inflammation, Benaroya Research Institute, Interleukin 7, Cytokine, Vaccine

Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, and Benaroya Research Institute (BRI), a Seattle based non-profit research institute within Virginia Mason Franciscan Health, announced that they have entered into a sponsored research agreement focused on further characterizing the pivotal role of Interleukin-7 receptor alpha (IL-7Rα) in Thymic Stromal Lymphopoietin (TSLP) and Interleukin-7 (IL-7) signaling pathways.

Key Points: 
  • Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, and Benaroya Research Institute (BRI), a Seattle based non-profit research institute within Virginia Mason Franciscan Health, announced that they have entered into a sponsored research agreement focused on further characterizing the pivotal role of Interleukin-7 receptor alpha (IL-7Rα) in Thymic Stromal Lymphopoietin (TSLP) and Interleukin-7 (IL-7) signaling pathways.
  • Zura Bio is currently advancing ZB-168, a monoclonal antibody targeting IL-7Rα, for the treatment of immune and inflammatory disorders.
  • At Benaroya Research Institute, this collaboration will leverage the expertise of Dr. Steve Ziegler, a world-renown authority in TSLP and IL-7 biology.
  • "We are thrilled to partner with the Benaroya Research Institute as we further explore the role of IL-7Rα in immune-mediated disorders," said Michael Howell, PhD, Chief Scientific Officer and Head of Translational Science at Zura Bio.

Abata Therapeutics Announces Second Development Candidate, ABA-201, a Novel Treg Cell Therapy for the Treatment of Type 1 Diabetes

Retrieved on: 
Thursday, August 24, 2023
Biotechnology, Diabetes, Health, Pharmaceutical, Clinical Trials, Linda, Partnership, University, Pediatrics, Therapy, NOD, Outcomes research, Pediatric endocrinology, Immune tolerance, Pancreas, University of California, Research, Multiple sclerosis, Inflammation, Autoimmunity, Assistant, TCR, Harvard Medical School, ITN, Behavior, Indiana University School of Medicine, Patient, Division, Lymph, Insulitis, Benaroya Research Institute, Endocrinology, Biology, Joslin Diabetes Center, Pharmaceutical industry, Nursing, T1D, Regulatory T cell, Medicine

“We are rapidly developing ABA-201 for T1D and expect to begin clinical studies in 2025.

Key Points: 
  • “We are rapidly developing ABA-201 for T1D and expect to begin clinical studies in 2025.
  • Additional non-clinical studies have established the role of Tregs in suppressing β-cell injury, a further potential benefit of the approach.
  • “This second program expands the scope of our pioneering Treg cell-based approach to patients with T1D.
  • This group brings deep expertise in T1D pathogenesis and the clinical development of novel therapeutics.

Sonoma Biotherapeutics Appoints Leaders in Cell Therapy and Immunology to Scientific Advisory Board

Retrieved on: 
Tuesday, April 11, 2023
Health, Other Science, Clinical Trials, Research, Science, Biotechnology, Protalix BioTherapeutics, University, Microbiology, Associate professor, University School, Howard Hughes Medical Institute, United States Air Force Scientific Advisory Board, University of California, Autoimmunity, University of Washington School of Medicine, Genetics, Cell biology, Pathology, Sloan, Immune system, Benaroya Research Institute, Immunology, Inflammation, Vaccine, Management, Pharmaceutical industry, Regulatory T cell

Sonoma Biotherapeutics, Inc. , a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, today announced the formation of its scientific advisory board.

Key Points: 
  • Sonoma Biotherapeutics, Inc. , a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, today announced the formation of its scientific advisory board.
  • The advisory board will provide strategic oversight on scientific advancements, trends in autoimmunity and Treg cell biology, new technologies, and the company’s preclinical pipeline.
  • Members of the Scientific Advisory Board include:
    Alexander Rudensky, Ph.D., is Chair of the immunology program at the Sloan Kettering Institute and co-founder of Sonoma Biotherapeutics.
  • “We have assembled a world-class group of advisors to guide our research efforts,” said Fred Ramsdell, Ph.D., co-founder and Chief Scientific Officer at Sonoma Biotherapeutics, and Chair of the Scientific Advisory Board.

Fresh Tracks Therapeutics Announces Positive Topline Results from Single and Multiple Ascending Dose Parts of Phase 1 Study of Oral DYRK1A Inhibitor FRTX-02

Retrieved on: 
Tuesday, March 7, 2023
Part, Doctor of Philosophy, Sale, DYRK1A, Inflammation, MAD, SAD, Acquisition, Therapy, Tmax, LP, Atopic dermatitis, Autoimmunity, Safety, Trial of the century, PK, Pharmacokinetics, Half-life, Assistant, AD, IL-6, Disease, QT interval, Clinical trial, University, Cmax, Affiliation, Plasma, University of Washington Department of Global Health, Patient, AUC, Day, LPS, Benaroya Research Institute, Translational medicine, PD, Pharmaceutical industry, Vaccine, MD

Furthermore, the results from this trial mark an important step forward for inhibition of the historically undruggable DYRK1A target and highlight the potential of FRTX-02 as a first-in-class, once-daily oral autoimmune therapy.

Key Points: 
  • Furthermore, the results from this trial mark an important step forward for inhibition of the historically undruggable DYRK1A target and highlight the potential of FRTX-02 as a first-in-class, once-daily oral autoimmune therapy.
  • Part 1A of the study was a SAD assessment, which enrolled a total of 56 healthy subjects across seven cohorts (single oral dose of 10 to 600 mg FRTX-02 or placebo).
  • FRTX-02 demonstrated a reduction in disease-relevant proinflammatory cytokines in whole blood, suggesting initial support for the FRTX-02 mechanism of action.
  • MTS Health Partners, LP has been retained as the Company’s exclusive financial advisor to assist in this review process.

Virginia Mason Medical Center in Seattle Recognized as Top Hospital for Outstanding Quality and Safety

Retrieved on: 
Wednesday, December 7, 2022
Hospital, Injury, Patient, Physician, Accident, Bailey-Boushay House, Virginia Mason Medical Center, Patient safety organization, House, Education, Letter, Round Top hospitals, Patient safety, Nursing, HIV/AIDS, Research, Autoimmune disease, Multimedia, Safety, Benaroya Research Institute, ASC, Leapfrog, Movement, Infection, Medicine, Puget Sound

SEATTLE, Dec. 7, 2022 /PRNewswire/ -- Virginia Mason Medical Center in Seattle was named a Top Teaching Hospital nationally by The Leapfrog Group in recognition of their achievements in patient safety and quality. Top Hospitals were honored at the 2022 Leapfrog Annual Meeting and Awards Dinner in Washington, D.C.

Key Points: 
  • SEATTLE, Dec. 7, 2022 /PRNewswire/ -- Virginia Mason Medical Center in Seattle was named a Top Teaching Hospital nationally by The Leapfrog Group in recognition of their achievements in patient safety and quality.
  • Among those, Virginia Mason Medical Center received a Top Teaching distinction.
  • A total of 115 top hospitals were selected as Top Hospitals, including:
    "We are honored to recognize Virginia Mason Medical Center as a Top Hospital this year," said Leah Binder, president and CEO of The Leapfrog Group.
  • "Virginia Mason Medical Center has demonstrated that they truly put patients first.

Virginia Mason Franciscan Health Hospitals Earn Outstanding National Patient Safety Recognitions

Retrieved on: 
Wednesday, November 16, 2022
Benaroya Research Institute, Patient safety organization, Pacific Northwest, Approximation error, Nursing, House, Patient, VMMC, Autoimmune disease, Physician, Safety, View, Research, Multimedia, Bailey-Boushay House, CEO, Hospital, Virginia Mason Medical Center, HIV/AIDS, Medicine, Puget Sound

SEATTLE and TACOMA, Wash., Nov. 16, 2022 /PRNewswire/ -- Virginia Mason Franciscan Health (VMFH) continues to be recognized as a leader in patient safety by Leapfrog Group with six hospitals earning 'A' safety grades in the fall 2022 Hospital Safety Grade Report. Virginia Mason Medical Center (VMMC) in Seattle remains one of the few hospitals in the nation – and the only hospital in Washington state – to earn straight A's since the Hospital Safety Grade program began in 2012.

Key Points: 
  • SEATTLE and TACOMA, Wash., Nov. 16, 2022 /PRNewswire/ -- Virginia Mason Franciscan Health (VMFH) continues to be recognized as a leader in patient safety by Leapfrog Group with six hospitals earning 'A' safety grades in the fall 2022 Hospital Safety Grade Report.
  • "National recognition of our system's safety accomplishments is a true measure of our commitment to providing world-class clinical excellence to patients in the Pacific Northwest," said Ketul J. Patel, CEO of Virginia Mason Franciscan Health.
  • The Virginia Mason Franciscan Health hospitals recognized in Leapfrog Group's fall 2022 Hospital Safety Report include:
    "Providing high-quality and safe care to our communities is a collaborative effort between our teams to ensure we are regularly evaluating and adapting our standards to meet the evolving needs of our patients," said Charleen Tachibana, senior vice president and chief quality, safety, patient experience officer for Virginia Mason Franciscan Health.
  • Virginia Mason Franciscan Health is an integrated health system serving the Puget Sound region, offering access to some of the country's most prestigious experts and hospitals that are internationally known for superior quality.

Virginia Mason Franciscan Health Welcomes James G. Terwilliger, Senior Vice President and Chief Operating Officer

Retrieved on: 
Wednesday, November 9, 2022
Trauma, USC, Senior, Indiana University Health, Methodism, COO, Physician, UCLA, University Hospitals Cleveland Medical Center, Patient, HIV/AIDS, St. Elizabeth's, Dana–Farber Cancer Institute, Medical Center, Montefiore Medical Center, Neurosurgery, Nursing, Academic health science centre, Bailey-Boushay House, View, Benaroya Research Institute, CommonSpirit Health, Heart failure, House, Hospital, Autoimmune disease, UPMC Presbyterian, Terwilliger, Health, Research, UPMC, Multimedia, Safety, CEO, Management, Medicine, Puget Sound

SEATTLE and TACOMA, Wash., Nov. 9, 2022 /PRNewswire/ --Virginia Mason Franciscan Health (VMFH) announced that James G. Terwilliger has been appointed Senior Vice President and Chief Operating Officer (COO) for Virginia Mason Franciscan Health and the Pacific Northwest Division of CommonSpirit Health.

Key Points: 
  • SEATTLE and TACOMA, Wash., Nov. 9, 2022 /PRNewswire/ --Virginia Mason Franciscan Health (VMFH) announced that James G. Terwilliger has been appointed Senior Vice President and Chief Operating Officer (COO) for Virginia Mason Franciscan Health and the Pacific Northwest Division of CommonSpirit Health.
  • "Over the past several months, Jim has demonstrated his passion for caring for the community and his commitment to providing high-quality care," said Ketul J. Patel, CEO of Virginia Mason Franciscan Health.
  • He also served as executive vice president and chief operating officer at Dana-Farber Cancer Institute; vice president of clinical services at Montefiore Medical Center in New York; president of Methodist and University Hospitals at IU Health; chief operations officer of UPMC Presbyterian; and held executive positions at USC and UCLA health systems.
  • Virginia Mason Franciscan Health is an integrated health system serving the Puget Sound region, offering access to some of the country's most prestigious experts and hospitals that are internationally known for superior quality.

Children's Cancer Research Fund (CCRF) Awards $100,000 Grants to Eight Early-Career Researchers as Childhood Cancer Awareness Month Wraps

Retrieved on: 
Wednesday, September 28, 2022
Israel Cancer Research Fund, University of Rochester, R01, National, Nationwide Children's Hospital, Children's Cancer Research Fund, Gastrointestinal tract, Safety, Virginia Tech, Incidence, Master of Science, University of Minnesota, Disease, Hospital, SMARCAL1, Seattle Children's, Ewing's sarcoma, Obesity, Lutetium (177Lu) oxodotreotide, Government, Benaroya Research Institute, Clinical trial, Cancer, Acute myeloid leukemia, Doctor of Philosophy, Acute lymphoblastic leukemia, Research, University, Research institute, Dana–Farber Cancer Institute, CCRF, Pharmaceutical industry, Medical imaging, Antibiotics, Dietary supplement, MD

MINNEAPOLIS, Sept. 28, 2022 /PRNewswire/ -- Children's Cancer Research Fund (CCRF) recently awarded these eight promising scientists the Emerging Scientist Award, each worth $100,000, to pursue their research in the childhood cancer field:

Key Points: 
  • Emily Heikamp, MD, PhD, MSc, Dana-Farber Cancer Institute, will research the mechanisms that drive NUP98-r acute myeloid leukemia.
  • Jemma Larson, PhD, University of Minnesota, aims to understand the deadly impact of acute Graft-versus-Host Disease in the gastrointestinal tract.
  • At CCRF, we believe scientists early in their careers have inventive approaches that can advance the childhood cancer research field.
  • Since 1981, CCRF donors have funded research that has revolutionized the way childhood cancer is treated worldwide.